.Nature Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, individuals along with metastatic gastrointestinal lumps that obtained biomarker-matched therapies based upon circulating tumor DNA profiling showed a more significant clinical perk than those getting unrivaled therapy.